Navigation Links
Smith & Nephew CEO Interviewed on Q2 2011 Results
Date:8/5/2011

LONDON, August 5, 2011 /PRNewswire/ --

 

Medical devices group Smith & Nephew reports sales growth of 12% and underlying sales growth of 5%.

In an interview with financial broadcaster http://www.cantos.com, new CEO Olivier Bohuon talks Q2 results and introduces his plans for a new Strategic Framework that details efficiency plans and announces a new focus on emerging markets. 

Bohuon also announced plans to inject an additional $300m into R&D over the next five years, and to focus the business on performance, innovation and a more global presence.

The interview and transcript are available now on http://www.cantos.com/company/Smith%20and%20Nephew

Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@cantos.com or phone +44-207-936-1352.


'/>"/>
SOURCE Smith & Nephew plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Regulus Therapeutics and GlaxoSmithKline Name a Third Alliance microRNA Target Triggering a Preclinical Milestone Payment
2. Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
3. Canadas Michael Smith Genome Sciences Center Validates NEBNext™ DNA Sample Preparation Reagents From New England Biolabs for Use in Next Generation Sequencing
4. GlaxoSmithKline and Amplimmune Form Global Strategic Collaboration
5. Smith & Nephew Receives FDA 510k Clearance for a 30-year Knee
6. Academics Launch New Web Site Holding Jeffrey Smith's Claims on GM Foods Up to Peer-Reviewed Science
7. SpineSmith to Present at the 5th Annual Stem Cell Summit
8. SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement
9. ClearTrial Names Proven Enterprise Software and Life Sciences Sales Leader Craig Smith as Vice President of Sales
10. FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKlines Candidate Cervical Cancer Vaccine
11. Amgen to Collaborate With GlaxoSmithKline to Commercialize Denosumab in Europe for Postmenopausal Osteoporosis (PMO)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... ... to nourishing a range of emerging technology-based businesses, recently earned a $77,518 grant ... location. , Founded in 2004, FITCI is Frederick’s first incubator. A non-profit ...
(Date:4/20/2017)... Maine (PRWEB) , ... April 20, 2017 , ... ... contributions to the scientific and clinical research community’s growing body of knowledge during ... 2017 in the Gracie Theatre and the adjacent Darling Atrium. During the event, ...
(Date:4/20/2017)... , ... April 20, 2017 , ... ... of a unique intellectual property (IP) sharing and commercialization model. , The Center ... inventions. A main component of this effort is bringing the IP to the ...
(Date:4/19/2017)... ... April 18, 2017 , ... A number of new instruments have recently emerged ... of the Protein and Cell Analysis Education Webinar Series , will focus on ... in current and future applications. , Many flow cytometers have unique capabilities and ...
Breaking Biology Technology:
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
Breaking Biology News(10 mins):